Former FDA vaccines deputy Krause heads down under as Mesoblast tries again on nearly entire pipeline
Philip Krause will take his 11 years of insight from the upper echelons of the FDA — especially during pandemic vaccine nods — and apply it to an Australian biotech that wants a second chance at securing approval in the US, particularly as it looks to bounce back from a nixed Novartis deal.
The former second-in-command for vaccines leadership at the FDA departed under murky circumstances last fall when he and Marion Gruber, director of the regulator’s Office of Vaccines Research & Review, reportedly were miffed by the federal administration’s sidestepping of the FDA on matters of Covid-19 booster shots.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.